Vanderbilt University has identified leucine-rich repeat kinase 2 (LRRK2; dardarin) and LRRK2 (G2019S mutant) inhibitors reported to be useful for the treatment of tauopathies, cancer, Crohn’s disease, type 1 diabetes, leprosy, rheumatoid arthritis, traumatic brain injury and Alzheimer’s disease, among others.